公开(公告)号：EP2049116A2

公开(公告)日：2009-04-22

申请号：EP07813923.5

申请日：2007-08-09

申请人： Bristol-Myers Squibb Company

发明人： BACHAND, Carol ,  BELEMA, Makonen ,  DEON, Daniel H. ,  GOOD, Andrew C. ,  GOODRICH, Jason ,  JAMES, Clint A. ,  LAVOIE, Rico ,  LOPEZ, Omar D. ,  MARTEL, Alain ,  MEANWELL, Nicholas A. ,  NGUYEN, Van N. ,  ROMINE, Jeffrey Lee ,  RUEDIGER, Edward H. ,  SNYDER, Lawrence B. ,  ST. LAURENT, Denis R. ,  YANG, Fukang ,  LANGLEY, David R. ,  HAMANN, Lawrence G.

IPC分类号： A61K31/506 ,  A61K31/501 ,  A61K31/497 ,  A61K31/444 ,  A61K31/4439 ,  A61P31/12 ,  C07D401/14 ,  C07D403/14

CPC分类号： C07D401/14 ,  C07D403/14

摘要： The present disclosure relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein A and B are selected from phenyl and a six-membered heteroaromatic ring containing one, two or three nitrogen atoms; provided that at least one of A and B is other than phenyl, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.